SNGX - Soligenix: Multiple Shots On Goal Strong Evidence Of Success And Attractive Valuation
With two Phase 3 assets approaching clinical trial readouts, a government-funded vaccine program including a potential COVID-19 play, and a valuation of approximately $70 million, Soligenix (SNGX) provides a compelling opportunity for investors. Unearthing hidden gems in the biopharma sector is a key focus of Illumination Capital, as we seek value and high growth potential in under-the-radar names such as SNGX. This company's most advanced product candidate is SGX301 for the treatment of cutaneous T-cell lymphoma or CTCL. So far, two favorable interim clinical trial readouts have demonstrated the product's efficacy, and a